Predictors and Outcomes of Subclinical Inflammation in Pediatric Patients with Familial Mediterranean Fever: A Retrospective Cohort Study from a Single Center - Top-Institutions - MDSpire

Predictors and Outcomes of Subclinical Inflammation in Pediatric Patients with Familial Mediterranean Fever: A Retrospective Cohort Study from a Single Center

  • By

  • Onur Bahçeci

  • Fatma Aydin

  • Özen Taş Aslan

  • Doğacan Sarisoy

  • Elif Erorhan

  • Zeynep Birsin Özçakar

  • April 24, 2026

  • 0 min

Share

Top Institutions in Rheumatology

Brief introduction explaining scope and methodology.

  • #1

    Hacettepe University Faculty of Medicine
    Hacettepe University Faculty of Medicine

    Ankara, Turkey

    Key Differentiators

    • Pediatric Rheumatology
    • Autoinflammatory Diseases
    • Genetic Research

  • #2

    National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH
    National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH

    Bethesda, Maryland

    Key Differentiators

    • Rheumatology
    • Immunology
    • Genetics

  • #3

    Tel Aviv Sourasky Medical Center
    Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel

    Key Differentiators

    • Pediatric Rheumatology
    • Genetic Disorders
    • Autoinflammatory Diseases

  • #4

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, Pennsylvania

    Key Differentiators

    • Pediatric Rheumatology
    • Immunology
    • Genetics

Original Source(s)

Predictors and Outcomes of Subclinical Inflammation in Pediatric Patients with Familial Mediterranean Fever: A Retrospective Cohort Study from a Single Center

  • by Onur Bahçeci, Fatma Aydin, Özen Taş Aslan, Doğacan Sarisoy, Elif Erorhan, Zeynep Birsin Özçakar

  • April 24, 2026

Related Content

Clinical Characteristics, Autoantibody Profiles, and Therapeutic Outcomes of Juvenile Systemic Sclerosis: An 11-Year Single-Center Experience from China

Building Better Oral Suspensions for Pediatric & Real-World Use

Greg Thomas, Kiel Laboratories’ Vice President of R&D, discusses oral suspensions, excipients, and patient-centered formulation

  • February 18, 2026

  • 6 min
Botulinum Toxin Evaluated in Digital Ischemia

Individual-level meta-analysis examines response, dosing, and safety across ischemic etiologies